Royal Philips (PHG) said Tuesday it received FDA 510(k) clearance for its Spectral CT 7500 RT, a computed tomography solution designed for personalized cancer radiotherapy.
The system combines traditional and spectral CT imaging, allowing oncologists to target tumors more precisely and reduce exposure to surrounding healthy tissue.
Shares of the company fell more than 1% in recent trading.
Price: 26.18, Change: -0.28, Percent Change: -1.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments